RCS - hVIVO PLC - Launch of full suite of hLAB standalone services

hVIVOAnnouncement

30/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240930:nRSd8781Fa&default-theme=true

RNS Number : 8781F  hVIVO PLC  30 September 2024

hVIVO plc

("hVIVO", the "Company" or the "Group")

 

Official launch of full suite of hLAB standalone services

Health & Safety Executive (HSE) clearance received for containment level 3
(CL-3) laboratory

 

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation
(CRO) and world leader in testing infectious and respiratory disease products
using human challenge clinical trials, announces the official launch of the
full suite of its hLAB service offering, its highly specialised virology and
immunology laboratory services for preclinical and clinical drug development.

 

hLAB is an industry leader in virology and clinical trial support and has been
providing laboratory services since 1989. In recent years, due to the strong
growth of the Company's human challenge trial (HCT) services, hLAB has been at
capacity facilitating the delivery of these trials. Following the move to the
new facility at Canary Wharf, the Company has tripled its laboratory capacity
and is offering specialised virology and immunology services as standalone
services. hLAB has already signed three stand-alone laboratory contracts in
2024, including its first major field study laboratory contract.

 

The expanded laboratory space has been specifically designed to streamline
workflows and provide operational efficiencies. It includes a cutting-edge
CL-3 laboratory, allowing hVIVO to work with hazard group 3 pathogens. The
CL-3 lab has now received HSE clearance, and the Company has commenced
operations.

 

hLAB has also completed a large expansion of its assay portfolio, broadening
the application of its serology, PCR, infectivity assay, human peripheral
blood mononuclear cells (PBMC) processing and biomarkers services for new
pathogens, including Omicron, human metapneumovirus (hMPV), B. Pertussis,
dengue, and additional influenza, respiratory syncytial virus (RSV) and human
rhinovirus (HRV) strains. With the additional capacity at Canary Wharf, hLAB
can now also expand its provision of field trial biologistics to many more
clients, offering bespoke sample collection kits provision, supporting pharma
companies and CROs in large multinational field studies.

 

In addition to these services, hLAB has also launched its biobank services and
has been approved by the UK Research Ethics Committee as a Research Tissue
Bank. The biobank is a comprehensive repository of a diverse range of human
biological samples, providing researchers with a valuable resource to drive
innovation, with a particular focus on vaccine development, immunology, and
respiratory research.

 

Further details are available at hlabservices.com
(http://www.hlabservices.com)

 

The team from hLAB will attend the upcoming World Vaccine Congress, Europe's
largest and most established meeting dedicated to vaccines, taking place at
Hotel Catalonia Barcelona Plaza, Spain from 28-31 October 2024. From basic
research to commercial manufacture, the event covers the whole vaccine value
chain, with hundreds of speakers and thousands of attendees from leading
global vaccines developers, academia and policymakers.

 

Attendees can meet the hLAB team at Booth Number 85. To request a meeting with
hLAB at the World Vaccine Congress, interested attendees can request a meeting
via the Terrapinn Event App (available from 8 October 2024) or by emailing
hlab@hvivo.com.

 

For further information please contact:

 

 hVIVO plc                                       +44 (0) 20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)                  +44 (0) 20 7220 0500
 Geoff Nash, Camilla Hume, Harriet Ward
 Nigel Birks - Life Science Specialist Sales

 Peel Hunt LLP (Joint Broker)                                        +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Joint Broker)                                                 +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 Walbrook PR (Financial PR & IR)                 +44 (0) 20 7933 8780 or hvivo@walbrookpr.com

 Stephanie Cuthbert, Phillip Marriage,           +44 (0) 7796 794 663 / +44 (0) 7867 984 082 /

Louis Ashe-Jepson
+44 (0) 7747 515 393

 

Notes to Editors

 

About hVIVO

 

hVIVO plc (http://www.hvivo.com) (ticker: HVO) is a fast-growing specialist
contract research organisation (CRO) and the world leader in testing
infectious and respiratory disease vaccines and therapeutics using human
challenge clinical trials. The Group provides end-to-end early clinical
development services to its large, established and growing repeat client base,
which includes four of the top 10 largest global biopharma companies.

 

The Group's fast-growing services business includes a unique portfolio of 11
human challenge models, with a number of new models under development, to test
a broad range of infectious and respiratory disease products. The Group has
world class challenge agent manufacturing capabilities, specialist drug
development and clinical consultancy services via its Venn Life Sciences
brand, and a lab offering via its hLAB brand, which includes virology,
immunology biomarker and molecular testing. The Group also offers additional
clinical field trial services such as patient recruitment and clinical trial
site services.

 

hVIVO runs challenge trials in London - its new state-of-the-art facilities
in Canary Wharf opened in 2024 and is the world's largest commercial human
challenge trial unit, with highly specialised on-site virology and immunology
laboratories, and an outpatient unit. To recruit volunteers / patients for its
studies, the Group leverages its unique clinical trial recruitment capability
via its FluCamp (http://www.flucamp.com/) volunteer screening facilities
in London and Manchester.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADZGZLKVLGDZM